Viking Therapeutics, Inc.

DB:1VT Stock Report

Market Cap: €4.6b

Viking Therapeutics Valuation

Is 1VT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1VT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1VT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1VT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1VT?

Key metric: As 1VT is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 1VT. This is calculated by dividing 1VT's market cap by their current book value.
What is 1VT's PB Ratio?
PB Ratio5.2x
BookUS$911.45m
Market CapUS$4.76b

Price to Book Ratio vs Peers

How does 1VT's PB Ratio compare to its peers?

The above table shows the PB ratio for 1VT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
BIO3 Biotest
2x29.3%€1.4b
FYB Formycon
1.6x30.6%€928.8m
HPHA Heidelberg Pharma
2.9x-33.0%€103.5m
2INV 2invest
1.1xn/a€67.3m
1VT Viking Therapeutics
5.2x-8.1%€4.8b

Price-To-Book vs Peers: 1VT is expensive based on its Price-To-Book Ratio (5.2x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does 1VT's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
1VT 5.2xIndustry Avg. 2.3xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 1VT is expensive based on its Price-To-Book Ratio (5.2x) compared to the European Biotechs industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is 1VT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1VT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 1VT's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1VT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€40.13
€105.42
+162.7%
18.6%€157.18€70.92n/a15
Dec ’25€50.84
€107.45
+111.3%
16.6%€156.54€76.36n/a14
Nov ’25€66.88
€101.44
+51.7%
14.2%€127.35€73.82n/a13
Oct ’25€55.34
€99.57
+79.9%
14.0%€125.26€72.62n/a13
Sep ’25€56.38
€103.41
+83.4%
11.8%€127.22€82.97n/a12
Aug ’25€53.82
€103.41
+92.1%
11.8%€127.22€82.97n/a12
Jul ’25€52.02
€104.73
+101.3%
11.7%€128.95€84.10n/a12
Jun ’25€57.06
€103.47
+81.3%
11.9%€126.97€82.81n/a11
May ’25€74.06
€101.09
+36.5%
19.5%€128.64€51.14n/a11
Apr ’25€77.54
€100.12
+29.1%
19.5%€127.42€50.65n/a11
Mar ’25€78.86
€91.99
+16.7%
20.4%€110.74€50.62n/a10
Feb ’25€22.00
€31.38
+42.6%
10.2%€36.92€25.84n/a9
Jan ’25€17.32
€31.38
+81.2%
10.2%€36.92€25.84n/a9
Dec ’24€11.79
€32.17
+173.0%
10.2%€37.85€26.49€50.849
Nov ’24€8.91
€32.17
+261.2%
10.2%€37.85€26.49€66.889
Oct ’24€10.41
€30.84
+196.2%
9.9%€36.50€25.55€55.3410
Sep ’24€12.67
€30.84
+143.5%
9.9%€36.50€25.55€56.3810
Aug ’24€13.09
€30.82
+135.5%
9.9%€36.47€25.53€53.8210
Jul ’24€15.31
€31.16
+103.5%
12.5%€37.43€23.39€52.0210
Jun ’24€21.28
€31.16
+46.4%
12.5%€37.43€23.39€57.0610
May ’24€18.60
€26.13
+40.5%
18.0%€31.75€17.24€74.0610
Apr ’24€16.09
€25.00
+55.4%
18.3%€32.29€17.53€77.5410
Mar ’24€10.56
€18.13
+71.7%
31.9%€28.30€11.32€78.869
Feb ’24€7.88
€17.11
+117.0%
34.4%€27.66€10.14€22.009
Jan ’24€8.56
€17.27
+101.8%
35.6%€28.25€10.36€17.329
Dec ’23€3.81
€17.51
+359.7%
41.7%€30.11€10.04€11.799

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 22:17
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Viking Therapeutics, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew LuchiniBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Julian HarrisonBTIG